I haven't had a chance to keep up with the most recent literature in this area, but last I heard, there were a couple of potential iron chelation therapy agents in the pipeline, most notably GT56-252 (James C Barton, "Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders," IDrugs: the investigational drugs journal, 2007, 10, 270-81) and deferitazole (FBS0701). Both are structurally derived from desferrithiocin. I don't know where these currently are in clinical trials, so if anybody is more familiar with this, I would love an answer as well! The development of an orally-available iron chelation therapy treatment for hemochromatosis and related diseases would be a great tool for treatment of these patients.

Thank you James interesting hope to get more details

Thanks for the sharing Mohamed, but I'm not in this field.

I think that many related issues can be solved with more research.

I do not have much information to share at this moment. Beyond doubt, it is well known that chelation may be emphasized as a mechanism of drug action especially for treatment of heavy metal poisoning and also for iron overload states .

Have similar opinion to most previous one.

In my clinic for long time the drug available was desferioxamine . Now we started working on oral deferasirox (Rx) - Exjade

Indicated for treatment of chronic iron overload caused by blood transfusion

20 mg/kg PO qDay; may increase by 5-10 mg increments based on serum ferritin; if not controlled on 30 mg/kg/day (ie, serum ferritin persistently >2500 mcg/L), may  increase up to 40 mg/kg qDay

The risk of experiencing persistent seizures was lower with DFO compared to placebo treatment (RR 0.80, 95% CI 0.67 to 0.95), but adverse effects were more common in the DFO group. One trial involving 45 adults and children compared the orally active iron chelator (deferiprone) with placebo and standard treatment; coma recovery (WMD -27 hrs; 95%CI -34.20 to -19.80) and parasite clearance (WMD -24 hrs; 95%CI -35.27 to -12.73) were significantly faster in the deferiprone group compared to placebo, but clinical significance cannot be assumed from this small trial.

http://www.ncbi.nlm.nih.gov/pubmed/12804409

Thanks for sharing Ali.